HARIMELLA

Harimella is a Salt Lake City-based biotechnology company specializing in the discovery of small molecule drugs for cancer and inflammatory disorders. The company employs a structure-based drug discovery approach to target high-value proteins that have historically been difficult to modulate. Its lead programs focus on inhibiting MALT1 for B-cell malignancies and CDK9 for various solid tumors. Harimella's mission is to translate complex biological insights into effective precision therapies for patients with limited treatment options. The firm is led by experienced drug discovery scientists with a track record of moving candidates from concept to clinical evaluation.